Alterity Therapeutics Ltd ATHE:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
0.675quote price arrow up+0.0328 (+5.11%)
Volume
21,879
52 week range
0.58 - 2.75
Loading...
  • Open0.75
  • Day High0.75
  • Day Low0.6401
  • Prev Close0.6422
  • 52 Week High2.75
  • 52 Week High Date07/01/21
  • 52 Week Low0.58
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap27.07M
  • Shares Out40.11M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.35
  • YTD % Change-6.25

KEY STATS

  • Open0.75
  • Day High0.75
  • Day Low0.6401
  • Prev Close0.6422
  • 52 Week High2.75
  • 52 Week High Date07/01/21
  • 52 Week Low0.58
  • 52 Week Low Date05/12/22
  • Market Cap27.07M
  • Shares Out40.11M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.35
  • YTD % Change-6.25

RATIOS/PROFITABILITY

  • EPS (TTM)-0.44
  • P/E (TTM)-1.54
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-10.757M
  • ROE (TTM)-81.39%
  • Revenue (TTM)10,000.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-74,065.55%
  • Debt To Equity (MRQ)0.22%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Alterity Therapeutics Ltd

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Alterity Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of...
Geoffrey Kempler
Non-Executive Chairman of the Board
David Stamler M.D.
Chief Executive Officer
Kathryn Andrews
Chief Financial Officer
Address
L 3 460 Bourke St
Melbourne, VIC
3000
Australia